

**Claims:**

The following listing of Claims will replace all prior versions and listings of Claims in the Application.

**Listing of the Claims:**

1-40 (canceled)

41. (previously presented.) A method of treating an individual suffering from fibromyalgia disorder, the method comprising the step of administering to the individual a therapeutically effective amount of racemic reboxetine or a pharmaceutically acceptable salt thereof.

42-43 (canceled)

44. (previously presented) The method of claim 41 wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 2 to about 20 mg/day.

45. (previously presented) The method of claim 44 wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 4 to about 10 mg/day.

46. (previously presented) The method of claim 45 wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 6 to about 10 mg/day.

47. (previously presented) The method of claim 41 wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

48. (previously presented) The method of claim 47 wherein said composition is

orally administered, and further comprising a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescent agent, dyestuff, sweetener, and wetting agent.

49. (original) The method of claim 48 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

50. (previously presented) The method of claim 47 wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

51. (original) The method of claim 41 wherein the pharmaceutically acceptable salt is methanesulfonate salt.

52-53 (canceled)

54 (canceled)